1. Scrip
  2. >>Drug Pricing

Adherence Issues Add Weight To Digital Trials Push

 
• By Lubna Ahmed

Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.

Luminous man
Can digital-based trials improve patient adherence to medicines?

Companies like GlaxoSmithKline PLC, Bayer AG, Novartis AG, AstraZeneca PLC and Teva Pharmaceutical Industries Ltd., are extending their hands to those in the technology industry, establishing partnerships to explore this uncharted area. From developing wearables and applications to building portals to gather data, pharma is exploring the usability of tech in R&D processes.

GSK's head of digital innovation and strategic partnerships, AJ Ploszay, told Scrip, "The capabilities a pharmaceutical company now needs are...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Drug Pricing

‘Building The Plane While Flying It’: Cell And Gene Therapy Makers Prepare For MFN Pricing, Tariffs

 
• By Mandy Jackson

It remains to be seen whether the Trump administration’s most favored nation drug pricing policy will trickle down from big pharma to small biotech, but executives said at ARM’s Cell and Gene Meeting on the Mesa that they are preparing strategies now to manage the future.

Stock Watch: Baby Steps In Most Favored Nation Drug Pricing

 
• By Andy Smith

Raising UK drug prices and offering lower list prices only to those US patients who are under- or uninsured were the industry’s initially cosmetic answers to the administration’s most favored nation drug pricing challenge. Then Pfizer stepped in.

A Backroom Deal Leaves Questions About How Pfizer’s US Agreement Lowers Prices

 
• By Jessica Merrill

By choosing a confidential agreement with the US government over announcing a transparent drug pricing deal, Pfizer continues industry’s legacy of pricing secrecy.

Closing The Gap? Pfizer Will Set Same US, Foreign Launch Prices In MFN Deal

 
• By Cathy Kelly

The company’s agreement with the Trump Administration, which likely is a template for MFN deals with other companies, also includes a $70bn commitment to ‘reshoring’ development and manufacturing in the US.

More from Scrip

Psoriasis Submissions Iin The Bag, J&J Advances Icotrokinra Into Phase III For Ulcerative Colitis

 
• By Kevin Grogan

The company has presented the full set of positive results from the Phase IIb ANTHEM-UC trial in the inflammatory bowel disease.

Hope Medicine Ready To Bring Potential First-in-Class Endometriosis Treatment Into Phase III

 
• By Andrew McConaghie

The non-hormonal drug could be a big step forward in treating pain associated with the condition, but the Chinese company may still need a partner for its Phase III studies and eventual commercialization.

Sakaguchi’s Nobel Brings Cheer To Japan Biopharma

 
• By Lisa Takagi

Japan's latest Nobel Prize win sparks hopes for renewed investment in biopharma R&D by the national government, including in a venture co-founded by the winner.